FindTrial
Sign In

Preventive Therapy In Hemophilia B using very low dose Factor IX.

Role Of Very Low Dose Of Factor IX Prophylaxis In Severe Hemophilia B Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025789
Enrollment
20
Registered
2020-06-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D67- Hereditary factor IX deficiency

Interventions

Intervention1: Very low dose prophylaxis of Factor IX (20IU/kg) weekly: Severe Hemophilia B patients will be given very low dose Factor IX (20IU/kg) prophylactically per week Control Intervention1: On

Sponsors

Maulana Azad Medical College
Lead Sponsor
Dr Naresh Kumar
Collaborator
Dr Sandeep Garg
Collaborator
Dr Sunita Aggarwal
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients with age greater than 13 years diagnosed as Severe Hemophilia B.

Exclusion criteria

Exclusion criteria: Patients with other bleeding disorders like Von Willebrands Disease Patients with any liver disease or kidney disease Patients on anticoagulation therapy

Design outcomes

Primary

MeasureTime frame
To estimate annual bleed rate in Severe Hemophilia B patientsTimepoint: Less than or equal to one year—

Secondary

MeasureTime frame
To calculate anti Hemophilic Factor usedTimepoint: Less than or equal to one year;To check compliance of patientsTimepoint: Less than or equal to one year;To check functional disability by FISH( Functional Independence Score In Hemophilia)Timepoint: Less than or equal to one year—

Countries

India

Contacts

Public ContactAnkitesh Kumar

Maulana Azad Medical College

drsunita.mamc@gmail.com9968281414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026